미국의 안구건조증 치료 시장 : 시장 규모, 점유율, 동향 분석(유형별, 약제별, 제형별, 판매채널별, 유통 채널별), 부문별 예측(2025-2030년)

U.S. Dry Eye Syndrome Treatment Market Growth & Trends:

The U.S. dry eye syndrome treatment market size is anticipated to reach USD 3.47 billion by 2030 and is anticipated to expand at a CAGR of 6.0% during the forecast period, according to a new report by Grand View Research, Inc. Market growth in the U.S. for dry eye disease (DED) has been significantly influenced by its high prevalence. By 2024, this condition has shown notable age-related increases, particularly among women, with around 6.8% of the adult population diagnosed.

The substantial patient base has highlighted the urgent need for effective treatment options, leading to a burgeoning market for companies catering to this demographic's needs. The aging population, particularly those aged 65 and older, has significantly contributed to the rising incidence of DED. This demographic shift has created increased demand for treatment as pharmaceutical companies and healthcare providers have adapted their strategies.

In 2023 and 2024, heightened awareness of DED, linked to increased screen time from digital devices, has further surged demand. Innovations in treatment options, including prescription medications and over-the-counter (OTC) products, have improved diagnosis rates. By 2025, new therapies such as Reproxalap, IC 265, and Acoltremon are anticipated to enhance relief and drive future market expansion.

U.S. Dry Eye Syndrome Treatment Market Report Highlights:

• The growing prevalence of DED in approximately 20 million Americans highlights urgent treatment needs and market opportunities for companies.
• Based on type, evaporative dry eye syndrome dominated the type segment, accounting for 82.5% of the total revenue share in 2024.
• Based on drugs, Cequa is projected to grow at the fastest CAGR of 27.0% over the forecast period.
• Based on product, cyclosporine led the market in 2024, demonstrating clinical efficacy in treating dry eye syndrome, significantly increasing tear production and reducing inflammation.
• Eye drops, especially artificial tears, offer rapid relief from dry eye symptoms by lubricating the eyes and mimicking natural tears, thus dominating the dosage form segment in 2024.
• Based on prescription, OTC drugs are expected to register the fastest CAGR of 6.5% over the forecast period.
• Retail pharmacies dominated the market, with online pharmacies exhibiting the fastest CAGR of 6.6% over the forecast period.
• In August 2024, OCuSOFT launched Retaine Allergy prescription-strength antihistamine drops in the U.S., enhancing its product line focused on dry eye solutions and allergy relief.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Drugs
  • 1.2.3. Product
  • 1.2.4. Dosage Form
  • 1.2.5. Sales Channel
  • 1.2.6. Distribution Channel
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. U.S. Dry Eye Syndrome Treatment Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis

Chapter 4. U.S. Dry Eye Syndrome Treatment Market: Type Business Analysis

• 4.1. Type Market Share, 2024 & 2030
• 4.2. Type Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Million)
• 4.4. Evaporative
  • 4.4.1. Evaporative Market, 2018 - 2030 (USD Million)
• 4.5. Aqueous Deficient
  • 4.5.1. Aqueous Deficient Market, 2018 - 2030 (USD Million)

Chapter 5. U.S. Dry Eye Syndrome Treatment Market: Drugs Business Analysis

• 5.1. Drugs Market Share, 2024 & 2030
• 5.2. Drugs Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Drugs, 2018 to 2030 (USD Million)
• 5.4. Xiidra
  • 5.4.1. Xiidra Market, 2018 - 2030 (USD Million)
• 5.5. Restasis
  • 5.5.1. Restasis Market, 2018 - 2030 (USD Million)
• 5.6. Cequa
  • 5.6.1. Cequa Market, 2018 - 2030 (USD Million)
• 5.7. Tyrvaya
  • 5.7.1. Tyrvaya Market, 2018 - 2030 (USD Million)
• 5.8. Eysuvis
  • 5.8.1. Eysuvis Market, 2018 - 2030 (USD Million)
• 5.9. Others
  • 5.9.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. U.S. Dry Eye Syndrome Treatment Market: Product Business Analysis

• 6.1. Product Market Share, 2024 & 2030
• 6.2. Product Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Million)
• 6.4. Artificial Tears
  • 6.4.1. Artificial Tears Market, 2018 - 2030 (USD Million)
• 6.5. Cyclosporine
  • 6.5.1. Cyclosporine Market, 2018 - 2030 (USD Million)
• 6.6. Topical Corticosteroids
  • 6.6.1. Topical Corticosteroids Market, 2018 - 2030 (USD Million)
• 6.7. Punctal Plugs
  • 6.7.1. Punctal Plugs Market, 2018 - 2030 (USD Million)
  • 6.7.2. Removable
    • 6.7.2.1. Removable Market, 2018 - 2030 (USD Million)
  • 6.7.3. Dissolvable
    • 6.7.3.1. Dissolvable Market, 2018 - 2030 (USD Million)
• 6.8. Oral Omega Supplements
  • 6.8.1. Oral Omega Supplements Market, 2018 - 2030 (USD Million)
• 6.9. Others
  • 6.9.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. U.S. Dry Eye Syndrome Treatment Market: Dosage Form Business Analysis

• 7.1. Dosage Form Market Share, 2024 & 2030
• 7.2. Dosage Form Segment Dashboard
• 7.3. Market Size & Forecasts and Trend Analysis, by Dosage Form, 2018 to 2030 (USD Million)
• 7.4. Eye Drops / Solutions
  • 7.4.1. Eye Drops / Solutions Market, 2018 - 2030 (USD Million)
• 7.5. Ointments and Gels
  • 7.5.1. Ointments and Gels Market, 2018 - 2030 (USD Million)
• 7.6. Capsules & Tablets
  • 7.6.1. Capsules & Tablets Market, 2018 - 2030 (USD Million)
• 7.7. Others
  • 7.7.1. Others Market, 2018 - 2030 (USD Million) Market, 2018 - 2030 (USD Million)

Chapter 8. U.S. Dry Eye Syndrome Treatment Market: Sales Channel Business Analysis

• 8.1. Sales Channel Market Share, 2024 & 2030
• 8.2. Sales Channel Segment Dashboard
• 8.3. Market Size & Forecasts and Trend Analysis, by Sales Channel, 2018 to 2030 (USD Million)
• 8.4. Prescription
  • 8.4.1. Prescription Market, 2018 - 2030 (USD Million)
• 8.5. OTC
  • 8.5.1. OTC Market, 2018 - 2030 (USD Million)

Chapter 9. U.S. Dry Eye Syndrome Treatment Market: Distribution Channel Business Analysis

• 9.1. Distribution Channel Market Share, 2024 & 2030
• 9.2. Distribution Channel Segment Dashboard
• 9.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
• 9.4. Retail Pharmacies
  • 9.4.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
• 9.5. Hospital Pharmacies
  • 9.5.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
• 9.6. Online Pharmacies
  • 9.6.1. Online Pharmacies Market, 2018 - 2030 (USD Million)

Chapter 10. Competitive Landscape

• 10.1. Participant Overview
• 10.2. Company Market Position Analysis
• 10.3. Company Categorization
• 10.4. Strategy Mapping
• 10.5. Company Profiles/Listing
  • 10.5.1. Novartis AG
    • 10.5.1.1. Overview
    • 10.5.1.2. Financial Performance
    • 10.5.1.3. Product Benchmarking
    • 10.5.1.4. Strategic Initiatives
  • 10.5.2. AbbVie Inc.
    • 10.5.2.1. Overview
    • 10.5.2.2. Financial Performance
    • 10.5.2.3. Product Benchmarking
    • 10.5.2.4. Strategic Initiatives
  • 10.5.3. Sun Pharmaceutical Industries Ltd.
    • 10.5.3.1. Overview
    • 10.5.3.2. Financial Performance
    • 10.5.3.3. Product Benchmarking
    • 10.5.3.4. Strategic Initiatives
  • 10.5.4. Janssen Pharmaceutica (Pty.) Ltd.
    • 10.5.4.1. Overview
    • 10.5.4.2. Financial Performance
    • 10.5.4.3. Product Benchmarking
    • 10.5.4.4. Strategic Initiatives
  • 10.5.5. OASIS Medical, Inc.
    • 10.5.5.1. Overview
    • 10.5.5.2. Financial Performance
    • 10.5.5.3. Product Benchmarking
    • 10.5.5.4. Strategic Initiatives
  • 10.5.6. Viatris Inc.
    • 10.5.6.1. Overview
    • 10.5.6.2. Financial Performance
    • 10.5.6.3. Product Benchmarking
    • 10.5.6.4. Strategic Initiatives
  • 10.5.7. Bausch Health Companies Inc.
    • 10.5.7.1. Overview
    • 10.5.7.2. Financial Performance
    • 10.5.7.3. Product Benchmarking
    • 10.5.7.4. Strategic Initiatives
  • 10.5.8. Santen Pharmaceutical Co., Ltd.
    • 10.5.8.1. Overview
    • 10.5.8.2. Financial Performance
    • 10.5.8.3. Product Benchmarking
    • 10.5.8.4. Strategic Initiatives